Core Viewpoint - Chao Yan Co., Ltd. has shown a slight decline in stock price and trading volume, with notable financing activities indicating investor sentiment and market dynamics [1][2]. Financing and Trading Activity - On October 22, Chao Yan Co., Ltd. experienced a stock price drop of 0.16% with a trading volume of 32.10 million yuan. The financing buy-in amounted to 2.52 million yuan, while financing repayment was 2.54 million yuan, resulting in a net financing outflow of 0.018 million yuan. The total financing and securities lending balance reached 95.12 million yuan [1]. - The current financing balance stands at 94.95 million yuan, representing 6.69% of the circulating market value. In terms of securities lending, 1,500 shares were repaid, and 600 shares were sold, with a selling amount of 14,600 yuan based on the closing price [1]. Company Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located in Shantou, Guangdong Province. The company specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise. The revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. reported a revenue of 184 million yuan, reflecting a year-on-year growth of 15%. The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.5% increase compared to the previous period [2]. Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period. The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. - The top ten circulating shareholders include new entrants such as Huabao Zhongzheng Medical ETF and Southern Zhongzheng 1000 ETF, with significant holdings of 1.91 million shares and 514,500 shares, respectively. Hong Kong Central Clearing Limited is the fourth-largest shareholder, increasing its holdings by 21,600 shares [3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. Shareholder Structure - As of June 30, 2025, the top circulating shareholders include Huabao Zhongzheng Medical ETF, Southern Zhongzheng 1000 ETF, and Hong Kong Central Clearing Limited, with several new institutional shareholders entering [9].

Core Viewpoint - On October 17, Chao Yan Co., Ltd. experienced a decline of 2.07% in stock price, with a trading volume of 44.8858 million yuan, indicating a negative market sentiment towards the company [1] Financing Summary - On October 17, Chao Yan Co., Ltd. had a financing buy-in amount of 3.2515 million yuan and a financing repayment of 3.9078 million yuan, resulting in a net financing outflow of 656,300 yuan [1] - As of October 17, the total financing and securities lending balance for Chao Yan Co., Ltd. was 98.2781 million yuan, with the current financing balance at 98.0541 million yuan, accounting for 6.98% of the circulating market value [1] - In terms of securities lending, there were no shares repaid on October 17, with 100 shares sold short, amounting to 2,409 yuan at the closing price, and a remaining short position of 9,300 shares valued at 224,000 yuan [1] Company Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located at 77 Jinsasha Road, Shantou City, Guangdong Province, and is recognized as a national key high-tech enterprise specializing in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary sources (1.26%) [1] Financial Performance - As of June 30, Chao Yan Co., Ltd. had 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [2] - For the first half of 2025, the company achieved an operating income of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.4455 million yuan, up 18.50% year-on-year [2] - Since its A-share listing, Chao Yan Co., Ltd. has distributed a total of 43.6896 million yuan in dividends [2] Institutional Holdings - As of June 30, 2025, the largest circulating shareholder of Chao Yan Co., Ltd. was Huabao Zhongzheng Medical ETF (512170), holding 1.9127 million shares as a new shareholder [2] - The second largest circulating shareholder was Southern Zhongzheng 1000 ETF (512100), with 514,500 shares, also a new shareholder [2] - Other notable shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 21,600 shares, and Huaxia Zhongzheng 1000 ETF (159845), which is a new shareholder holding 304,800 shares [2]

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive performance in stock trading and financial results, indicating growth potential in the medical imaging and industrial non-destructive testing equipment sectors [1][2]. Financial Performance - As of June 30, 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders for the same period was approximately 68.45 million yuan, reflecting an 18.5% increase compared to the previous year [2]. Stock Trading Activity - On October 14, 2023, Chao Yan Co., Ltd. saw a stock price increase of 2.24%, with a trading volume of approximately 92.23 million yuan [1]. - The financing buy-in amount for the same day was 6.48 million yuan, while the financing repayment was 6.92 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1]. - The total financing and securities balance as of October 14, 2023, was approximately 95.63 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. Dividend Distribution - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable institutional shareholders include Southern Zhongzheng 1000 ETF and Hong Kong Central Clearing Limited, with significant shareholdings and increases [3].

Core Insights - The stock of Chao Yan Co., Ltd. experienced a decline of 1.60% on October 13, with a trading volume of 51.83 million yuan [1] - The company reported a financing net buy of -67,400 yuan on the same day, with a total financing and securities balance of 96.02 million yuan [1] Financing and Trading Data - On October 13, Chao Yan Co., Ltd. had a financing buy amount of 5.56 million yuan and a financing repayment of 5.62 million yuan [1] - The current financing balance is 95.85 million yuan, accounting for 6.68% of the circulating market value [1] - The company had no shares repaid in the securities lending segment, with 3,100 shares sold, amounting to 76,200 yuan at the closing price [1] Company Overview - Chao Yan Co., Ltd. is located in Shantou, Guangdong Province, and was established on November 15, 1982, with a listing date set for January 22, 2025 [1] - The company specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise [1] - The revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2] - The average number of circulating shares per person increased by 19.98% to 2,456 shares [2] - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2] Dividend and Shareholding Structure - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3] - As of June 30, 2025, the largest circulating shareholder is Huabao CSI Medical ETF, holding 1.91 million shares as a new shareholder [3] - Other notable shareholders include Southern CSI 1000 ETF and Hong Kong Central Clearing Limited, with increases in their holdings compared to the previous period [3]

证券日报网讯 10月13日晚间，超研股份发布公告称，公司于2025年10月11日召开了职工代表大会，经 与会职工代表表决，同意选举陈宏龙先生担任公司第二届董事会职工代表董事。 （文章来源：证券日报） ...

证券代码：301602 证券简称：超研股份 公告编号：2025-047 汕头市超声仪器研究所股份有限公司 关于选举产生第二届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"） 及汕头市超声仪器研究所股份有限公司章程（以下简称"《公司章程》"）等有 关规定，为保证汕头市超声仪器研究所股份有限公司（以下简称"公司"）董事 会的合规运作，公司于 2025 年 10 月 11 日召开了职工代表大会，经与会职工代 表表决，同意选举陈宏龙先生担任公司第二届董事会职工代表董事，任期自职工 代表大会审议通过之日起至公司第二届董事会任期届满之日止。 董事会 2025 年 10 月 13 日 附件：陈宏龙先生简历 陈宏龙先生，中国国籍，无境外永久居留权，1969 年 10 月出生，本科学历。 1992 年 7 月至 2008 年 12 月，历任汕头超声仪器研究所技术员、副主任、主任、 办公室主任、所长助理、副所长；2008 年 12 月至 2020 年 9 月，历任汕头市超 声仪器研 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-046 汕头市超声仪器研究所股份有限公司 关于新增募集资金专户并签订募集资金专户存储三方监管 协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日分别召开第二届董事会第九次会议和第二届监事会第六次会议，审议通过 了《关于部分募投项目增加实施主体及募集资金专户的议案》，同意募投项目"工 业无损检测系统研发项目"的实施主体由公司增加为公司和全资子公司汕头市超 声检测科技有限公司(以下简称"超声检测")，实施地点不变，同意超声检测设 立募集资金专户，用于"工业无损检测系统研发项目"募集资金的存放、管理和 使用。同意公司以募集资金向超声检测增资 2,200 万元人民币，具体内容详见公 司在巨潮资讯网披露的《关于部分募投项目增加实施主体及募集资金专户的公告》 （公告编号：2025-040）。 近日，公司和全资子公司超声检测会同保荐机构中国银河证券股份有限公司 与创兴银行有限公司汕头分行签订了《募集资金专户存储三方监 ...

Core Viewpoint - Chao Yan Co., Ltd. experienced a slight decline in stock price on September 25, with a trading volume of 46.03 million yuan and a net financing outflow of 1.95 million yuan, indicating a cautious market sentiment towards the company [1][2]. Financing Summary - On September 25, Chao Yan Co., Ltd. had a financing buy amount of 2.72 million yuan, with a total financing balance of 99.58 million yuan, accounting for 6.90% of its market capitalization [2]. - The company had no shares repaid in the securities lending market, with 100 shares sold, amounting to 2,474 yuan at the closing price, and a remaining securities lending balance of 96,500 yuan [2]. Business Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located in Shantou, Guangdong Province, and specializes in the research, development, production, and sales of medical imaging and industrial non-destructive testing equipment [2]. - The company's revenue composition includes medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary products (1.26%) [2]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. reported a revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, reflecting an 18.50% increase compared to the previous year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period, while the average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. - The top shareholders include Huabao Zhongzheng Medical ETF, which is the largest shareholder with 1.91 million shares, and several new institutional investors have entered the shareholder list [3].

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive financial performance with a revenue increase of 15% year-on-year and a net profit growth of 18.5% for the first half of 2025, indicating strong operational capabilities and market demand [2]. Financial Performance - For the period from January to June 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, reflecting a year-on-year growth of 15% [2]. - The net profit attributable to the parent company for the same period was approximately 68.45 million yuan, which represents an 18.5% increase compared to the previous year [2]. - Cumulative cash dividends distributed by the company since its A-share listing amount to approximately 43.69 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares held per shareholder increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [2]. Trading Activity - On September 24, 2025, Chao Yan Co., Ltd. saw a stock price increase of 1.52%, with a trading volume of approximately 48.73 million yuan [1]. - The financing buy-in amount for the same day was 2.94 million yuan, while the financing repayment was 10.16 million yuan, resulting in a net financing outflow of 7.22 million yuan [1]. - The total balance of margin trading for Chao Yan Co., Ltd. as of September 24, 2025, was approximately 102 million yuan, accounting for 7.03% of its market capitalization [1].